title: The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo.
abstract: Linomide (Roquinimex) has antitumor activity when given in vivo (but not when applied in vitro) that has been attributed to immune host mechanisms. Recent studies, however, suggest that Linomide may also possess antiangiogenic properties. The aim of the present study was to evaluate the antiangiogenic effect of Linomide using an intravital microscopic technique. Syngeneic pancreatic islets were isolated and implanted into the dorsal skinfold chamber of Syrian golden hamsters. This model allows detailed repeated in vivo observations and quantitative analysis of revascularization of pancreatic islet grafts. The neovascularization process of the islets is a highly reproducible phenomenon that is completed within about 2 weeks, resulting in a microvascular network very similar to that of islets in situ. The plasma concentration profile of Linomide following a single oral dose of the compound was determined. The elimination of Linomide was fast, the half-life being 2.6 +/- 0.2 h. Due to the short half-life, the hamsters were given Linomide twice a day. One group of animals (n = 9) was force-fed Linomide (100 mg/kg per day) from the day of implantation throughout the 2-week observation period, and the results were compared with those obtained in a nontreated control group (n = 7). At days 6, 10, and 14 after implantation, the neo-vasculature of the islets was examined. In the control group, 91% +/- 4% (mean +/- SEM) of the islets showed the first signs of angiogenesis at day 6, whereas in the Linomide-treated group the corresponding value was 48% +/- 12%. At days 10 and 14, the "take-rate" in the control group increased to 94% +/- 3% for day 0 and to 94% +/- 4% (n = 6) for day 14, whereas in the treated group the corresponding take-rate was 67% +/- 11% and 72% +/- 12%, respectively. The functional capillary density in the control group at days 6, 10, and 14 was 223 +/- 17,348 +/- 29, and 495 +/- 29 cm-1, respectively, and that in the Linomide treated group was 91 +/- 28, 181 +/- 43, and 229 +/- 47 cm-1, respectively. These results demonstrate that Linomide suppresses the neovascularization of the islet grafts by both delaying the onset of and reducing the percentage of islets displaying angiogenesis as well as by decreasing the rate of proliferation of capillary endothelium of the revascularized islets.
authors.affiliation: La Jolla Institute for Experimental Medicine, La Jolla, CA 92037.
authors.forename: P
authors.initials: P
authors.lastname: Borgström
authors.forename: I P
authors.initials: IP
authors.lastname: Torres Filho
authors.forename: P
authors.initials: P
authors.lastname: Vajkoczy
authors.forename: K
authors.initials: K
authors.lastname: Strandgården
authors.forename: J
authors.initials: J
authors.lastname: Polaçek
authors.forename: B
authors.initials: B
authors.lastname: Hartley-Asp
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D006224:Cricetinae; D006912:Hydroxyquinolines / Q000493:pharmacokinetics / Q000494:pharmacology*; D007515:Islets of Langerhans / Q000098:blood supply; D016381:Islets of Langerhans Transplantation / Q000502:physiology; D008647:Mesocricetus; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000517:prevention & control*; D016042:Transplantation, Heterotopic
chemical_list: D000970:Antineoplastic Agents; D006912:Hydroxyquinolines; C045282:roquinimex